Thymosin Alpha-1 (Thymalfasin, Zadaxin)
28-amino acid immunomodulatory peptide
At a glance
What it is: 28-amino acid immunomodulatory peptide.
Primary research applications:
- Chronic hepatitis B (approved in some countries)
- Adjuvant immune support (investigational)
Editorial summary: Unlike most peptides on this site, Thymosin Alpha-1 is approved for clinical use in several countries (not the US) for hepatitis B and has legitimate human trial data in that indication. Claims beyond hepatitis B are much less well-established.
What is Thymosin Alpha-1?
Thymosin Alpha-1 (TA-1, brand name Zadaxin/Thymalfasin) is a synthetic version of a 28-amino acid peptide originally isolated from thymus tissue. It's approved as an immunomodulatory drug for chronic hepatitis B in ~35 countries (not the United States) and is widely studied as an adjuvant in other infectious and oncologic settings.[1]
Mechanism of action
TA-1 modulates multiple aspects of immune function:
- Promotes T-cell maturation and activation
- Enhances Th1-type cellular immune responses
- Increases natural killer cell activity
- Activates dendritic cells via Toll-like receptor signaling
What the research shows
The peer-reviewed literature on Thymosin Alpha-1 is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Improves virologic outcomes in chronic hepatitis B | Multiple Phase 3 trials | Supported |
| Reduces sepsis mortality | One positive large RCT; inconsistent replication | Mixed |
| Reduces COVID-19 mortality | Observational data; RCT evidence mixed | Uncertain |
| Reverses general immunosenescence in healthy adults | No high-quality evidence | Unsupported |
| Is a 'general immune booster' | Over-general framing; evidence is indication-specific | Unsupported |
Reported user experiences
How the research describes administration
In approved clinical use: subcutaneous injection, typically twice weekly. Dosing depends on indication.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Thymosin Alpha-1 is an actual immunomodulatory drug approved for a real indication in many countries. That gives it more legitimacy than most peptides in the wellness ecosystem. It doesn't, however, make it a general-purpose 'immune booster' — the evidence is strongest for specific infectious-disease contexts.
Frequently asked questions
Is Thymosin Alpha-1 FDA-approved?
Not in the United States. It has orphan drug designation for specific indications but is not a generally approved drug. It is approved for chronic hepatitis B in ~35 other countries.
What's the evidence in COVID-19?
Observational data from Chinese ICUs during the initial pandemic wave suggested a mortality benefit in severe cases. Subsequent randomized trial data have been mixed. No regulatory agency has approved TA-1 specifically for COVID-19.
Does Thymosin Alpha-1 boost the immune system?
In specific contexts with compromised immunity (chronic hepatitis B, possibly sepsis), yes — it modulates immune function in measurable ways. In healthy adults, the idea of 'boosting' immunity is poorly defined and not supported by RCT evidence.
Is this the same as TB-500 or Thymosin Beta-4?
No. Thymosin Alpha-1 (from thymus tissue extracts) and Thymosin Beta-4 / TB-500 are structurally different peptides with different functions. The name similarity is historical; they're distinct molecules.
References
- Goldstein AL, Badamchian M. Thymosins: chemistry and biological properties in health and disease. Expert Opin Biol Ther. 2004;4(4):559-73. https://pubmed.ncbi.nlm.nih.gov/15102606/
- Zhang YY, et al. Clinical study on combined treatment of chronic hepatitis B with thymosin alpha-1. Hepatol Res. 2010. (Representative of meta-analysis literature.) https://pubmed.ncbi.nlm.nih.gov/?term=thymosin+alpha+1+hepatitis+B
- Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013;17(1):R8. https://pubmed.ncbi.nlm.nih.gov/23327199/